Cargando…

P1261: ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL

Detalles Bibliográficos
Autores principales:	Tatarczuch, M., Waltham, M., Shortt, J., Hawkes, E., Ho, S.-J., Trotman, J., Brasacchio, D., Co, M., Li, J., Ramakrishnan, V., Dunne, K., Opat, S., Gregory, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430053/ http://dx.doi.org/10.1097/01.HS9.0000847908.60002.1c

Ejemplares similares

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
por: Opat, Stephen, et al.
Publicado: (2023)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
por: Opat, S., et al.
Publicado: (2022)

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
por: Opat, Stephen, et al.
Publicado: (2021)

P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL
por: Opat, Stephen, et al.
Publicado: (2023)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
por: Wong, Jonathan, et al.
Publicado: (2018)

Characteristics of rapid cycling in 1261 bipolar disorder patients
por: Miola, Alessandro, et al.
Publicado: (2023)

1261. Do All Patients Prefer Telehealth Care?
por: Gudipati, Smitha, et al.
Publicado: (2022)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

Cases from the Practice of Dr. Hansen: Allg. Hom. Zeitung 23, ’90
Publicado: (1890)

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
por: Tam, Constantine, et al.
Publicado: (2023)

Tu1261: IMPACT OF THE COVID-19 PANDEMIC ON THE EPIDEMIOLOGY OF ALCOHOL-ASSOCIATED HEPATITIS
por: Frolkis, Alexandra, et al.
Publicado: (2022)

Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study
por: Cull, Gavin, et al.
Publicado: (2021)

1261. Prospective Audit and Feedback Approach Differs between Antimicrobial Stewardship Professions
por: Ausman, Sara, et al.
Publicado: (2023)

Erratum to “Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era” AmJMed, 133(11); 1254–1261
por: Massoomi, Michael R., et al.
Publicado: (2021)

An Unnoticed Symptom of Ipecacuanha, Clinically Verified by Dr. Mossa: Allg. Hom. Zeitung, No. 3, 1889
Publicado: (1889)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
por: Doorduijn, J., et al.
Publicado: (2022)

Statistics of Small-Pox: Remarks on a Report of Dr. L. J. Keller, in the “Allg. Wiener Med. Zeitung”
por: Gradle, H.
Publicado: (1874)

Determination of chloroplast genome sequence of Magnolia ofeliae A. Vázquez & Cuevas (Magnoliaceae), an endangered Mexican Magnolia
por: Yeo, Yoonju, et al.
Publicado: (2020)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
por: Silvestre, Antonio Salar, et al.
Publicado: (2023)

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
por: Dimopoulos, M., et al.
Publicado: (2022)

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
por: Zhou, Keshu, et al.
Publicado: (2021)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

The “Correction” of Professor Dr. G. Jaeger from the Hahnemannian Standpoint: In the Allg. Hom. Zeitung, Vol. 125, P. 157
por: Fincke, B.
Publicado: (1893)

Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
por: Yuen, Hiu Lam Agnes, et al.
Publicado: (2020)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

Casa de la magnolia /
por: Palou, Pedro Angel, 1966-
Publicado: (2004)

Activation of circ_0072088/miR‐1261/PIK3CA pathway accelerates lung adenocarcinoma progression
por: Cao, Feng, et al.
Publicado: (2022)

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

Analysis of Metabolites in White Flowers of Magnolia Denudata Desr. and Violet Flowers of Magnolia Liliiflora Desr.
por: Park, Chang Ha, et al.
Publicado: (2018)

P1120: THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA
por: Liu, A., et al.
Publicado: (2022)

THE LS-ANTIGEN OF VACCINIA : IV. CHEMICAL ANALYSIS OF LS AND THE EFFECT OF CHYMOTRYPSIN ON LS
por: Smadel, Joseph E., et al.
Publicado: (1943)

Cannot write session to /tmp/vufind_sessions/sess_c6i489ip6sfmk93tokdhgo8gs4